Stock Analysis Report

Header cover image

Executive Summary

Merck & Co., Inc. provides healthcare solutions worldwide. More Details

Snowflake Analysis

Outstanding track record established dividend payer.

Similar Companies

Share Price & News

How has Merck's share price performed over time and what events caused price changes?

Latest Share Price and Events

Stable Share Price: MRK is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.

Volatility Over Time: MRK's weekly volatility (3%) has been stable over the past year.

Market Performance

7 Day Return




US Pharmaceuticals


US Market

1 Year Return




US Pharmaceuticals


US Market

Return vs Industry: MRK underperformed the US Pharmaceuticals industry which returned 3.5% over the past year.

Return vs Market: MRK underperformed the US Market which returned 19.5% over the past year.

Shareholder returns

7 Day0.1%2.4%0.3%
30 Day4.6%5.8%3.3%
90 Day6.6%13.0%14.2%
1 Year-4.6%-7.5%8.4%4.8%23.8%21.1%
3 Year47.3%34.8%25.4%15.7%45.0%35.4%
5 Year87.9%61.7%53.3%35.1%127.7%102.3%

Long-Term Price Volatility Vs. Market

How volatile is Merck's share price compared to the market and industry in the last 5 years?

Simply Wall St News


Is Merck undervalued compared to its fair value and its price relative to the market?


Undervalued compared to fair value

Share Price vs. Fair Value

Below Fair Value: MRK ($83.19) is trading below our estimate of fair value ($144.09)

Significantly Below Fair Value: MRK is trading below fair value by more than 20%.

Price To Earnings Ratio

PE vs Industry: MRK is good value based on its PE Ratio (18.3x) compared to the US Pharmaceuticals industry average (24.1x).

PE vs Market: MRK is good value based on its PE Ratio (18.3x) compared to the US market (21x).

Price to Earnings Growth Ratio

PEG Ratio: MRK is poor value based on its PEG Ratio (2.9x)

Price to Book Ratio

PB vs Industry: MRK is overvalued based on its PB Ratio (7.2x) compared to the US Pharmaceuticals industry average (4.4x).

Next Steps

Future Growth

How is Merck forecast to perform in the next 1 to 3 years based on estimates from 18 analysts?


Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MRK's forecast earnings growth (6.3% per year) is above the savings rate (2%).

Earnings vs Market: MRK's earnings (6.3% per year) are forecast to grow slower than the US market (21.6% per year).

High Growth Earnings: MRK's earnings are forecast to grow, but not significantly.

Revenue vs Market: MRK's revenue (4% per year) is forecast to grow slower than the US market (10.3% per year).

High Growth Revenue: MRK's revenue (4% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: MRK's Return on Equity is forecast to be very high in 3 years time (49.6%).

Next Steps

Past Performance

How has Merck performed over the past 5 years?


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: MRK has high quality earnings.

Growing Profit Margin: MRK's current net profit margins (24.3%) are higher than last year (20.3%).

Past Earnings Growth Analysis

Earnings Trend: MRK's earnings have grown by 17.4% per year over the past 5 years.

Accelerating Growth: MRK's earnings growth over the past year (23.6%) exceeds its 5-year average (17.4% per year).

Earnings vs Industry: MRK earnings growth over the past year (23.6%) exceeded the Pharmaceuticals industry 16.8%.

Return on Equity

High ROE: MRK's Return on Equity (39.4%) is considered high.

Next Steps

Financial Health

How is Merck's financial position?

Financial Position Analysis

Short Term Liabilities: MRK's short term assets ($26.6B) exceed its short term liabilities ($20.4B).

Long Term Liabilities: MRK's short term assets ($26.6B) do not cover its long term liabilities ($40.1B).

Debt to Equity History and Analysis

Debt Level: MRK's debt to equity ratio (94.8%) is considered high.

Reducing Debt: MRK's debt to equity ratio has increased from 58.4% to 94.8% over the past 5 years.

Debt Coverage: MRK's debt is well covered by operating cash flow (39.8%).

Interest Coverage: MRK's interest payments on its debt are well covered by EBIT (20.9x coverage).

Balance Sheet

Next Steps


What is Merck current dividend yield, its reliability and sustainability?


Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: MRK's dividend (3.13%) is higher than the bottom 25% of dividend payers in the US market (1.39%).

High Dividend: MRK's dividend (3.13%) is low compared to the top 25% of dividend payers in the US market (3.85%).

Stability and Growth of Payments

Stable Dividend: MRK's dividends per share have been stable in the past 10 years.

Growing Dividend: MRK's dividend payments have increased over the past 10 years.

Current Payout to Shareholders

Dividend Coverage: With its reasonable payout ratio (52.4%), MRK's dividend payments are covered by earnings.

Future Payout to Shareholders

Future Dividend Coverage: MRK's dividends in 3 years are forecast to be well covered by earnings (40% payout ratio).

Next Steps


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Ken Frazier (65 yo)





Mr. Kenneth C. Frazier, also known as Ken, has been Independent Lead Director at Exxon Mobil Corp. since 2020. He has been the President of Merck & Co., Inc. since May 01, 2010 and has also been its Chief ...

CEO Compensation Analysis

Compensation vs Market: Ken's total compensation ($USD27.65M) is above average for companies of similar size in the US market ($USD10.55M).

Compensation vs Earnings: Ken's compensation has increased by more than 20% in the past year.

Leadership Team

Kenneth Frazier
$ 34.6m
Robert Davis
Executive VP of Global Services & CFO6.75yrsUS$7.73m0.0068%
$ 14.2m
Jennifer Zachary
Executive VP2.75yrsUS$5.05m0.00026%
$ 547.2k
Sanat Chattopadhyay
Executive VP & President of Merck Manufacturing Division11.17yrsUS$5.42m0.0027%
$ 5.6m
David Williams
Chief Information & Digital Officerno datano data0.00010%
$ 210.5k
Peter Dannenbaum
Vice President of Investor Relations1.42yrsno datano data
Michael Fleming
Senior VP and Chief Ethics & Compliance Officer1.83yrsno data0.00027%
$ 568.3k
Jennifer Mauer
Vice President of Global Communicationsno datano datano data
Michael Nally
Chief Marketing Officer & Executive VP2yrsno data0.00056%
$ 1.2m
Steven Mizell
Executive VP & Chief Human Resources Officer4.08yrsno data0.00021%
$ 442.0k
Julie Gerberding
EVP and Chief Patient Officer of Strategic Communications6yrsno data0.0010%
$ 2.2m
Richard DeLuca
Executive VP & President of Merck Animal Health9.33yrsno data0.0035%
$ 7.4m


Average Tenure


Average Age

Experienced Management: MRK's management team is seasoned and experienced (5 years average tenure).

Board Members

Kenneth Frazier
$ 34.6m
Peter Wendell
Independent Director17.33yrsUS$330.00k0.000040%
$ 84.2k
Pamela Craig
Independent Director5.33yrsUS$348.50k0.000070%
$ 147.3k
Patricia Russo
Independent Director25.33yrsUS$300.00k0.00052%
$ 1.1m
Thomas Glocer
Independent Director13.17yrsUS$345.00k0.00020%
$ 420.9k
Leslie Brun
Lead Independent Directorno dataUS$360.00k0.000080%
$ 168.4k
Thomas Cech
Independent Director11.67yrsUS$360.00k0%
$ 0
Inge Thulin
Independent Director2.83yrsUS$300.00k0%
$ 0
Kathy Warden
Independent Director0.83yrno data0.000020%
$ 42.1k
Christine Seidman
Independent Director0.83yrno data0%
$ 0
Paul Rothman
Independent Director5.33yrsUS$340.00k0%
$ 0
Mary Coe
Independent Director1.83yrsUS$289.85k0%
$ 0


Average Tenure


Average Age

Experienced Board: MRK's board of directors are considered experienced (5.3 years average tenure).


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: MRK insiders have only sold shares in the past 3 months.

Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Merck & Co., Inc.'s company bio, employee growth, exchange listings and data sources

Key Information

  • Name: Merck & Co., Inc.
  • Ticker: MRK
  • Exchange: NYSE
  • Founded: 1891
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$210.474b
  • Shares outstanding: 2.53b
  • Website: https://www.merck.com

Number of Employees


  • Merck & Co., Inc.
  • 2000 Galloping Hill Road
  • Kenilworth
  • New Jersey
  • 7033
  • United States


TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
MRKNYSE (New York Stock Exchange)YesCommon StockUSUSDJan 1968
MRKBVL (Bolsa de Valores de Lima)YesCommon StockPEUSDJan 1968
MRK *BMV (Bolsa Mexicana de Valores)YesCommon StockMXMXNJan 1968
MRKENXTPA (Euronext Paris)YesCommon StockFREURJan 1968
6MKDB (Deutsche Boerse AG)YesCommon StockDEEURJan 1968
MRKSWX (SIX Swiss Exchange)YesCommon StockCHCHFJan 1968
0QAHLSE (London Stock Exchange)YesCommon StockGBUSDJan 1968
6MKXTRA (XETRA Trading Platform)YesCommon StockDEEURJan 1968
MRKSNSE (Santiago Stock Exchange)YesCommon StockCLUSDJan 1968
MRK-UETLX (Eurotlx)YesCommon StockITEURJan 1968
MRKWBAG (Wiener Boerse AG)YesCommon StockATEURJan 1968
MRKBASE (Buenos Aires Stock Exchange)CEDEAR (5 REP 1 USD0.50)ARARSMar 2000
MRCK34BOVESPA (Bolsa de Valores de Sao Paulo)BDR EACH 8 REP 1 COMBRBRLDec 2011


Merck & Co., Inc. provides healthcare solutions worldwide. The company offers therapeutic for cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection,...

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/19 23:55
End of Day Share Price2021/01/19 00:00
Annual Earnings2019/12/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.